Medgenics Inc Directors Dealings (1777T)

TIDMMEDG TIDMMEDU

RNS Number : 1777T

Medgenics Inc

15 November 2013

 
 Press Release   15 November 2013 
 

Directors Dealings

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 11 November 2013 it was informed by Dr. Sol Barer, Chairman of the Board of Directors of the Company, that he purchased on the open market 25,000 shares of common stock on that day at an average price of $6.8049 per share.

Following this purchase, Dr. Barer now owns 72,000 shares of common stock, which represents approximately 0.4 percent of the total issued shares of common stock. Dr. Barer, directly or through trusts for the benefit of Dr. Barer and his family, also has the right to purchase up to 1,315,000 shares of common stock pursuant to options previously granted (in aggregate Dr. Barer's shares of common stock and options represent 1,387,000 shares of common stock which represent approximately 7.5 percent of the Company's total issued shares of common stock).

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Contacts:

 
 Medgenics, Inc. 
  John Leaman, CFO 
  [e-mail] 
 Abchurch Communications 
  Joanne Shears / Jamie Hooper 
  / Harriet Rae 
  [e-mail]      [phone] 
 Oriel Securities (NOMAD & Joint 
  Broker) 
  Jonathan Senior / Giles Balleny     [phone] 
 SVS Securities plc (Joint Broker) 
  Alex Brearley                       [phone] 
 

-Ends-

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSUVUOROBAAAAA